VANCOUVER, BC--(Marketwired - October 18, 2016) - THC BioMed Ltd. (CSE: THC) (OTC PINK: THCBF) (FRANKFURT: TFHC) ("THC" or the "Company") is pleased to report that it has had its license amended by Health Canada and will begin to initiate its business plan by inter-trading between licensed producers to strengthen its products and service.

THC is currently working on good production practices surrounding the supply of starting material to registered patients, once regulatory requirements have been met and our E-Commerce Platform has been initiated.

THC intends to offer its 29 strains of dried Marihuana as well as Cannabis oil and Cannabis Resin, to patients registered under the ACMPR.

Management continues to work diligently to increase shareholder value while practicing fiscal discipline.

THC's vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.